Congress is considering a bill that would let patients access psychedelic treatments outside of FDA (the US drug regulator) oversight. It probably won't become law in the next two years because it lacks safety rules that FDA needs, and Congress has too many other priorities. This matters because it affects whether patients can legally get these treatments soon.
Four agents (fda_reviewer, dea_officer, legislator, journalist) converge on this: no companion safety amendment framework exists, FDA concerns about unregulated access are unaddressed in current draft language, and the legislative calendar is crowded. Two dissenting agents (veteran_advocate, maps_researcher) represent advocacy optimism rather than procedural analysis. Historical base rate for contested health access bills passing without safety compromise language in a single Congress is low. Resolve: bill either dies in committee, gets tabled, or passes only with material amendments that change its current form.